Osteoporosis del varón

  1. Torres, M. Muñoz
  2. Martín, A. García
  3. Bolívar, V. Contreras
  4. Sevilla, J. Escobar
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2022

Título del ejemplar: Enfermedades óseas

Serie: 13

Número: 60

Páginas: 3537-3543

Tipo: Artículo

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2022.06.011 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La osteoporosis del varón es una enfermedad infradiagnosticada e infratratada que presenta una alta prevalencia. Hasta un 25% de los varones presentarán una fractura osteoporótica a lo largo de la vida. Las formas secundarias de la enfermedad son frecuentes, y es necesario descartarlas en el proceso de evaluación diagnóstica. Las causas secundarias y los factores de riesgo más comunes de la osteoporosis en los varones incluyen diferentes enfermedades endocrinas (particularmente el hipogonadismo), procesos relacionados con el estilo de vida y algunos tratamientos farmacológicos. La absorciometría dual de rayos X (DXA) es la prueba esencial en el diagnóstico. Las determinaciones de laboratorio se deben orientar a descartar las formas secundarias de la enfermedad. El tratamiento debe considerar la optimización de la ingesta de calcio y vitamina D y la corrección de las alteraciones etiológicas identificadas. Los bifosfonatos, denosumab y teriparatida han mostrado ser eficaces para aumentar la masa ósea en estos pacientes.

Referencias bibliográficas

  • Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-72.
  • Allison SJ, Folland JP, Rennie WJ, Summers GD, Brooke Wavell K. High impact exercise increased femoral neck bone mineral density in older men: a randomised unilateral intervention. Bone. 2013;53:321-8.
  • Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Mineral Res. 2009;24:719-25.
  • Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367:1714-23.
  • Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S. National Osteoporosis Foundation. Clinician’s Guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014;25:2359-81.
  • Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Comm Health. 1990;44: 241-5.
  • Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T. Risk factors for low bone mass-related fractures in men: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1861-70.
  • Ebeling PR. Clinical practice: Osteoporosis in men. N Engl J Med. 2008;358:1474-82.
  • El-Hajj Fuleihan G, Bouillon R, Clarke B, Chakhtoura M, Cooper C, McClung M. Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range. J Bone Miner Res. 2015;30(7):1119-33.
  • Genant HK, Wu CY, van Kuijk C, Nevitt M. Vertebral fracture assessment using a semi-quantitative technique. J Bone Miner Res. 1993; 8:1137-48.
  • Gennari L, Bilezikian JP. Osteoporosis in men. Endocrinol Metab Clin N Am. 2007;36:399-419.
  • Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;2012(9): CD007146.
  • Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone. 2015;78:216-24.
  • Hayón Ponce M, García Fontana B, Avilés Pérez MD, González Salvatierra S, Andújar Vera F, Moratalla Aranda E. Lower trabecular bone score in type 2 diabetes mellitus: A role for fat mass and insulin resistance beyond hyperglycaemia. Diabetes Metab. 2021;47(6):101276.
  • Hurley DL, Binkley N, Camacho PM, Diab DL, Kennel KA, Malabanan A. The use of vitamins and minerals in skeletal health: American Association of Clinical endocrinologists and the American College of Endocrinology position statement. Endocrine Practice. 2018;24 915-24.
  • Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D. Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int. 2001;69: 218-21.
  • Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-6.
  • Lewiecki EM, Laster AJ. Clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry. J Clin Endocrinol Metabol. 2006;91:4215-22.
  • Muñoz Torres M, Manzanares Córdova R, García Martín A, Avilés Pérez MD, Nieto Serrano R, Andújar Vera F. Usefulness of Trabecular Bone Score (TBS) to Identify Bone Fragility in Patients with Primary Hyperparathyroidism. J Clin Densitom. 2019; 22(2):162-70.
  • Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J. Alendronate for the treatment of osteoporosis in men. New Engl J Med. 2000;343:604-10.
  • Orwoll ES, Adler RA. Osteoporosis in men. En: Bilezikian JP. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington DC: America Society for Bone and Mineral Metabolism; 2018. p 443-9.
  • Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Díez Pérez A. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18:9-17.
  • Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97: 3161-9.
  • Porcelli T, Maffezzoni F, Pezzaioli LC, Delbarba A, Cappelli C, Ferlin A. Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis? Eur J Endocrinol. 2020;183(3):R75-R93.
  • Reid RR. Osteoporosis: Evidence for vitamin D and calcium in older people. Drug Ther Bull. 2020;58:122-5.
  • Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 2-year study. Rheumatol Int. 2009;29:311-5.
  • Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A. Osteoporosis in men: A review of an underestimated bone condition. Int J Mol Sci. 2021;(22)4:2105.
  • Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6:272-85.
  • Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-39.
  • Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39.
  • Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie WD. Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions Part 2: Trabecular Bone Score. J Clin Densito. 2015;18: 309-30.
  • Slovik DM, Rosenthal DI, Doppelt SH, Potts JTJ, Daly MA, Campbell JA. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986;1:377-81.
  • Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TLJ. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55.
  • Watts NB, Adler RA, Bilezikian JP, Drake, MT, Eastell R, Orwoll ES. Osteoporosis in men: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-22.
  • Weaver CM, Alexander DD, Boushey CJ, Dawson Hughes B, Lappe JM, LeBoff MS. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016;27: 367-76.
  • Zeytinoglu M, Jain RK, Vokes TJ. Vertebral fracture assessment: Enhancing the diagnosis, prevention, and treatment of osteoporosis. Bone. 2017;104:54-65.
Fuente de los datos: Dialnet